How effective is allogeneic stem cell transplant for myelofibrosis?

The procedure replaces diseased blood-forming marrow with healthy stem cells from a donor. The new immune system may attack myelofibrosis cells, while the conditioning treatment clears space for donor cells to grow. This is the main treatment with potential to alter the underlying disease rather than only ease symptoms or reduce blood counts.

Benefit is not immediate. Blood production may take time to recover, and the spleen, symptoms, and marrow findings are followed over repeated assessments. Some people have persistent or returning disease, and some cannot proceed because their health or disease risk makes transplant too hazardous.

Ask a transplant team to assess your risk category, blood counts, spleen findings, symptoms, other illnesses, fitness, and donor options. Discuss reduced-intensity conditioning when appropriate, expected hospital care, fertility concerns, medicines, and the support needed at home. A second opinion from a transplant specialist can help clarify whether the expected benefit fits your priorities.

During recovery, contact the transplant team promptly for fever, chills, breathlessness, new rash, persistent vomiting or diarrhoea, bleeding, confusion, or a sudden reduction in urine. These symptoms can signal infection, graft-versus-host disease, medication toxicity, or another complication requiring rapid assessment. Use the team’s emergency instructions rather than waiting for a routine appointment.

Which features of my myelofibrosis affect the expected transplant benefit? What donor and conditioning options are suitable? How will response and relapse be monitored? Which symptoms should trigger an urgent call after discharge?